Jun 26th 2012 - Edison Investment Research today published a report on MediGene entitled "Nice Niche For RhuDex". In summary, the report says:
Medigene’s selection of primary biliary cirrhosis (PBC) as a niche indication to determine RhuDex’s proof-of-concept could prove to be a shrewd move. While rheumatoid arthritis remains RhuDex’s main target in the long run, conducting a Phase II study in PBC presents a market opportunity in itself and offers a reduced timeframe to generate clinical data by end-2013 to influence future development and/or partnering decisions. We raise our valuation by €15m to €96m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
